Logo image of VRAY

VIEWRAY INC (VRAY) Stock Fundamental Analysis

NASDAQ:VRAY - Nasdaq - US92672L1070 - Common Stock - Currency: USD

0.025  -0.02 (-39.9%)

After market: 0.0251 +0 (+0.4%)

Fundamental Rating

2

Overall VRAY gets a fundamental rating of 2 out of 10. We evaluated VRAY against 189 industry peers in the Health Care Equipment & Supplies industry. The financial health of VRAY is average, but there are quite some concerns on its profitability. VRAY is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year VRAY has reported negative net income.
In the past year VRAY has reported a negative cash flow from operations.
In the past 5 years VRAY always reported negative net income.
In the past 5 years VRAY always reported negative operating cash flow.
VRAY Yearly Net Income VS EBIT VS OCF VS FCFVRAY Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 -20M -40M -60M -80M -100M

1.2 Ratios

VRAY has negative profitability rations, so we won't be analyzing them here.
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
VRAY Yearly ROA, ROE, ROICVRAY Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 0 -1K -2K -3K

1.3 Margins

Looking at the Gross Margin, with a value of 8.05%, VRAY is doing worse than 85.00% of the companies in the same industry.
VRAY's Gross Margin has declined in the last couple of years.
The Profit Margin and Operating Margin are not available for VRAY so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 8.05%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5Y-11.97%
VRAY Yearly Profit, Operating, Gross MarginsVRAY Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 0 -100 -200 -300 -400

More info and screens

4

2. Health

2.1 Basic Checks

VRAY does not have a ROIC to compare to the WACC, probably because it is not profitable.
VRAY has more shares outstanding than it did 1 year ago.
Compared to 1 year ago, VRAY has a worse debt to assets ratio.
VRAY Yearly Shares OutstandingVRAY Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 50M 100M 150M
VRAY Yearly Total Debt VS Total AssetsVRAY Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 100M 200M 300M

2.2 Solvency

Based on the Altman-Z score of -6.16, we must say that VRAY is in the distress zone and has some risk of bankruptcy.
VRAY has a Altman-Z score of -6.16. This is in the lower half of the industry: VRAY underperforms 72.00% of its industry peers.
There is no outstanding debt for VRAY. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -6.16
ROIC/WACCN/A
WACC6.05%
VRAY Yearly LT Debt VS Equity VS FCFVRAY Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 0 100M -100M 200M

2.3 Liquidity

VRAY has a Current Ratio of 1.16. This is a normal value and indicates that VRAY is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 1.16, VRAY is doing worse than 91.00% of the companies in the same industry.
A Quick Ratio of 0.86 indicates that VRAY may have some problems paying its short term obligations.
VRAY has a Quick ratio of 0.86. This is amonst the worse of the industry: VRAY underperforms 90.00% of its industry peers.
Industry RankSector Rank
Current Ratio 1.16
Quick Ratio 0.86
VRAY Yearly Current Assets VS Current LiabilitesVRAY Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 100M 200M 300M

More info and screens

6

3. Growth

3.1 Past

The Earnings Per Share has been growing slightly by 6.25% over the past year.
The Revenue has grown by 44.09% in the past year. This is a very strong growth!
Measured over the past years, VRAY shows a very strong growth in Revenue. The Revenue has been growing by 24.59% on average per year.
EPS 1Y (TTM)6.25%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-14.29%
Revenue 1Y (TTM)44.09%
Revenue growth 3Y5.2%
Revenue growth 5Y24.59%
Sales Q2Q%19.38%

3.2 Future

Based on estimates for the next years, VRAY will show a quite strong growth in Earnings Per Share. The EPS will grow by 15.77% on average per year.
The Revenue is expected to grow by 18.71% on average over the next years. This is quite good.
EPS Next Y12.95%
EPS Next 2Y18.04%
EPS Next 3Y15.77%
EPS Next 5YN/A
Revenue Next Year-9.41%
Revenue Next 2Y11.46%
Revenue Next 3Y18.71%
Revenue Next 5YN/A

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
VRAY Yearly Revenue VS EstimatesVRAY Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M
VRAY Yearly EPS VS EstimatesVRAY Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -0.2 -0.4 -0.6 -0.8 -1

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

VRAY reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year VRAY is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
VRAY Price Earnings VS Forward Price EarningsVRAY Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40 50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
VRAY Per share dataVRAY EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 0.4 -0.4 -0.6

4.3 Compensation for Growth

A more expensive valuation may be justified as VRAY's earnings are expected to grow with 15.77% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y18.04%
EPS Next 3Y15.77%

More info and screens

0

5. Dividend

5.1 Amount

VRAY does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

VIEWRAY INC

NASDAQ:VRAY (7/25/2023, 8:15:48 PM)

After market: 0.0251 +0 (+0.4%)

0.025

-0.02 (-39.9%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)08-03 2023-08-03/amc
Earnings (Next)10-30 2023-10-30/amc
Inst Owners0.2%
Inst Owner Change-2.78%
Ins Owners17.32%
Ins Owner Change0%
Market Cap4.58M
Analysts73.33
Price Target1.22 (4780%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)3.72%
Min EPS beat(2)0.18%
Max EPS beat(2)7.26%
EPS beat(4)4
Avg EPS beat(4)2%
Min EPS beat(4)0.05%
Max EPS beat(4)7.26%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-0.96%
Min Revenue beat(2)-2.26%
Max Revenue beat(2)0.34%
Revenue beat(4)3
Avg Revenue beat(4)3.66%
Min Revenue beat(4)-2.26%
Max Revenue beat(4)12.76%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-63.08%
EPS NQ rev (1m)0%
EPS NQ rev (3m)1.11%
EPS NY rev (1m)14.95%
EPS NY rev (3m)14.95%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-17.24%
Revenue NY rev (1m)-20.3%
Revenue NY rev (3m)-20.3%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.04
P/FCF N/A
P/OCF N/A
P/B 0.08
P/tB 0.08
EV/EBITDA N/A
EPS(TTM)-0.6
EYN/A
EPS(NY)-0.35
Fwd EYN/A
FCF(TTM)-0.64
FCFYN/A
OCF(TTM)-0.62
OCFYN/A
SpS0.58
BVpS0.3
TBVpS0.3
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 8.05%
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5Y-11.97%
F-Score3
Asset Turnover0.45
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 83.14%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.16
Quick Ratio 0.86
Altman-Z -6.16
F-Score3
WACC6.05%
ROIC/WACCN/A
Cap/Depr(3y)67.17%
Cap/Depr(5y)94.95%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)6.25%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-14.29%
EPS Next Y12.95%
EPS Next 2Y18.04%
EPS Next 3Y15.77%
EPS Next 5YN/A
Revenue 1Y (TTM)44.09%
Revenue growth 3Y5.2%
Revenue growth 5Y24.59%
Sales Q2Q%19.38%
Revenue Next Year-9.41%
Revenue Next 2Y11.46%
Revenue Next 3Y18.71%
Revenue Next 5YN/A
EBIT growth 1Y-0.96%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year25.44%
EBIT Next 3Y15.77%
EBIT Next 5YN/A
FCF growth 1Y-91.91%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-106.14%
OCF growth 3YN/A
OCF growth 5YN/A